@article{fdi:010066162,
  title = {{I}dentification of patients who could benefit from bedaquiline or delamanid : a multisite {MDR}-{TB} cohort study},
  author = {{B}onnet, {M}aryline and {B}astard, {M}. and du {C}ros, {P}. and {K}hamraev, {A}. and {K}imenye, {K}. and {K}hurkhumal, {S}. and {H}ayrapetyan, {A}. and {T}hemba, {D}. and {T}elnov, {A}. and {S}anchez-{P}adilla, {E}. and {H}ewison, {C}. and {V}araine, {F}.},
  editor = {},
  language = {{ENG}},
  abstract = {{BACKGROUND}: {T}he {W}orld {H}ealth {O}rganization recommends adding bedaquiline or delamanid to multi drug-resistant tuberculosis ({MDR}-{TB}) regimens for which four effective drugs are not available, and delamanid for patients at high risk of poor outcome. {OBJECTIVE}: {T}o identify patients at risk of unfavourable outcomes who may benefit from the new drugs. {METHODS}: {R}etrospective cohort study of treatment outcomes involving four to five effective drugs for 1524 months in programmes in {U}zbekistan, {G}eorgia, {A}rmenia, {S}waziland and {K}enya between 2001 and 2011. {RESULTS}: {O}f 1433 patients, 48.5% had body mass index ({BMI}) <18.5 kg/m(2), 72.9% had a high bacillary load, 16.7% were resistant to two injectables, 2.9% were resistant to ofloxacin ({OFX}) and 3.0% had extensively drug-resistant {TB} ({XDR}-{TB}). {T}reatment success ranged from 59.7% (no second-line resistance) to 27.0% ({XDR}-{TB}). {XDR}-{TB} (a{OR} 8.16, 95%{CI} 3.22-20.64), resistance to two injectables (a{OR} 1.90, 95%{CI} 1.00-3.62) or {OFX} (a{OR} 5.56, 95%{CI} 2.15-14.37), past incarceration (a{OR} 1.88, 95%{CI} 1.11-3.2), history of second-line treatment (a{OR} 3.24, 95%{CI} 1.53-6.85), low {BMI} (a{OR} 2.22, 95%{CI} 1.56-3.12) and high bacillary load (a{OR} 2.32, 95%{CI} 1.15-4.67) were associated with unfavourable outcomes. {P}atients started on capreomycin rather than kanamycin were more likely to have an unfavourable outcome (a{OR} 1.54, 95%{CI} 1.04-2.28). {CONCLUSION}: {I}n our cohort, patients who may benefit from bedaquiline and delamanid represented up to two thirds of all {MDR}-{TB} patients.},
  keywords = {treatment ; regimens ; resource-limited ; drug resistance ; tuberculosis ; outcomes ; {ARMENIE} ; {KENYA} ; {OUZBEKISTAN} ; {GEORGIE} ; {SWAZILAND}},
  booktitle = {},
  journal = {{I}nternational {J}ournal of {T}uberculosis and {L}ung {D}isease},
  volume = {20},
  numero = {2},
  pages = {177--186},
  ISSN = {1027-3719},
  year = {2016},
  DOI = {10.5588/ijtld.15.0962},
  URL = {https://www.documentation.ird.fr/hor/fdi:010066162},
}